United States
US 12,697,329 B2
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US 12,697,329 B2 is a granted patent from the United States Patent and Trademark Office (USPTO), dated 2026-08-04. Applicant: ARCUTIS BIOTHERAPEUTICS, INC. Its PDF downloads from this page without an account, up to 5 a day.
- Applicant
- ARCUTIS BIOTHERAPEUTICS, INC.
- Inventors
- David W. Osborne
- Publication date
- 2026-08-04
- Filing date
- 2024-06-17
- Document type
- B2 Granted patent
- Also written as
- US 12,697,329 B2 · US12697329 · 12697329
Abstract
A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
The opening of the abstract. The full text is in the PDF.
No account needed: 5 free downloads a day (5 left today). Batch downloads and Office Action citations need a free account.
Patent office website: United States Patent and Trademark Office (USPTO)
Look up another patent
Need many patents at once?
Paste a whole list of numbers. DownloadPatent finds the right version of each and packs the PDFs into one ZIP.
Sign up free